Evidence mapPaperPMID 39726715Full record

ArticleAdvanced functional materials2024

Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.

Alec Wang, Madeline Walden, Romy Ettlinger, Fabian Kiessling, Jeremiah J Gassensmith, Twan Lammers, Stefan Wuttke, Quim Peña

Abstract read
In one paragraph

Article in Advanced functional materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. DNA-mimic for Specific Surface Functionalization of Zr-MOFs for Bacterial Targeting.Angewandte Chemie (International ed. in English) · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alec Wang *Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074 Aachen, Germany.
Madeline Walden *BCMaterials (Basque Centre for Materials, Applications & Nanostructures), Bld. Martina Casiano, 3rd. Floor UPV/EHU Science Park Barrio Sarriena s/n, 48940 Leioa, Spain.
Romy EttlingerEastChem School of Chemistry, University of St Andrews, North Haugh, St Andrews KY16 9ST, UK.
Fabian KiesslingInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074 Aachen, Germany.
Jeremiah J GassensmithDepartment of Chemistry and Biochemistry & Biomedical Engineering, University of Texas at Dallas, Richardson, TX 75080-3021.
Twan LammersInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074 Aachen, Germany.
Stefan WuttkeBCMaterials (Basque Centre for Materials, Applications & Nanostructures), Bld. Martina Casiano, 3rd. Floor UPV/EHU Science Park Barrio Sarriena s/n, 48940 Leioa, Spain.
Quim PeñaInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074 Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal-organic framework (MOF) materials are gaining significant interest in biomedical research, owing to their high porosity, crystallinity, and structural and compositional diversity. Their versatile hybrid organic/inorganic chemistry endows MOFs with the capacity to retain organic (drug) molecules, metals, and gases, to effectively channel electrons and photons, to survive harsh physiological conditions such as low pH, and even to protect sensitive biomolecules. Extensive preclinical research has been carried out with MOFs to treat several pathologies and, recently, their integration with other biomedical materials such as stents and implants has demonstrated promising performance in regenerative medicine. However, there remains a significant gap between MOF preclinical research and translation into clinically and societally relevant medicinal products. Here, we outline the intrinsic features of MOFs and discuss how these are suited to specific biomedical applications like detoxification, drug and gas delivery, or as (combination) therapy platforms. We furthermore describe relevant examples of how MOFs have been engineered and evaluated in different medical indications, including cancer, microbial, and inflammatory diseases. Finally, we critically examine the challenges facing their translation into the clinic, with the goal of establishing promising research directions and more realistic approaches that can bridge the translational gap of MOFs and MOF-containing (nano)materials.

Indexed as

biomedicinemetallotherapymetal-organic frameworksnanoparticlesporous materials

Identifiers

PMID39726715
PMCPMC7617264

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.